Evaluation of patients with virus C hepatitis treated with direct-acting antivirals in the Chilean public systemHepatitis crónica por virus C. Evaluación de los pacientes tratados con antivirales de acción directa en el sistema público de Chile

Simple item page
dc.article.number065005
dc.contributor.authorMezzano G.
dc.contributor.authorAguirre H.
dc.contributor.authorPena A.
dc.contributor.authorGomez F.
dc.contributor.authorNazal L.
dc.contributor.authorArab J.P.
dc.contributor.authorRoblero J.P.
dc.date.accessioned2025-05-01T10:31:28Z
dc.date.available2025-05-01T10:31:28Z
dc.date.issued2021
dc.description.abstract© 2021 Sociedad Medica de Santiago. All rights reserved.Background: Direct-acting antivirals (DAA) allowed a radical change in the treatment of hepatitis C virus (HCV), achieving the elimination of the virus or sustained viral response (SVR) in > 95% of patients, with good tolerance and few adverse effects. Aim: To characterize the treated population and evaluate the efficacy of DAA treatment in the Chilean public health system. Material and Methods: Retrospective analysis of data sheets of patients with chronic HCV infection collected by the Ministry of Health of Chile between 2016 and May 2019. Results: Two hundred and fifty-five patients with a mean age of 59 years (51% males) were collected. Genotype 1b was predominant, 72% patients had a diagnosis of cirrhosis at the beginning of treatment. Sofosbuvir-Velpatasvir was predominantly used in 56%. SVR was achieved in 92% of cases, only 4% persisted with detectable load at 24 weeks. A significant decrease in alanine aminotransferase values (88 and 31 U/L respectively, p < 0.01) and a significant increase in plasma albumin (3.7 and 3.9 mg/dl respectively, p = 0.02) were observed. The comparative analysis of MELD-Na before and after treatment did not show a significant variation (10.8 and 10.4 respectively, p = 0.34). Conclusions: These patients treated with DAAs presented SVR rates comparable with national and international data.
dc.description.funderANID FONDAP
dc.description.funderCIGIDEN
dc.description.funderResearch Center for Integrated Disaster Risk Management
dc.description.funderVRI-UC
dc.description.funderCONICYT
dc.description.funderANID
dc.format.extent8 páginas
dc.fuente.origenScopus
dc.identifier.doi10.4067/s0034-98872021001201687
dc.identifier.eisbn978-1-5106-5352-8
dc.identifier.eissn2641-435X
dc.identifier.isbn978-1-5106-5351-1
dc.identifier.issn07176163 00349887
dc.identifier.pubmedid40243597
dc.identifier.scieloidS0718-69242020000300109
dc.identifier.scopusidSCOPUS_ID:85170663553
dc.identifier.urihttps://doi.org/10.4067/s0034-98872021001201687
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/103760
dc.identifier.wosidWOS:000800028500001
dc.information.autorucEscuela de Medicina; Arab Verdugo Juan Pablo; 0000-0002-8561-396X; 132745
dc.issue.numero3
dc.language.isoes
dc.nota.accesoContenido completo
dc.pagina.final1693
dc.pagina.inicio1687
dc.publisherSpringer International Publishing
dc.relation.ispartofWorld Conference on Timber Engineering (2023 : Oslo, Noruega)
dc.revistaRevista Medica de Chile
dc.rightsacceso abierto
dc.subjectHepacivirus
dc.subjectHepatitis
dc.subjectSustained Virologic Response
dc.subject.ddc600
dc.subject.deweyTecnologíaes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEvaluation of patients with virus C hepatitis treated with direct-acting antivirals in the Chilean public systemHepatitis crónica por virus C. Evaluación de los pacientes tratados con antivirales de acción directa en el sistema público de Chile
dc.typeartículo
dc.volumen149
sipa.codpersvinculados132745
sipa.indexScopus
sipa.trazabilidadCarga WOS-SCOPUS;01-05-2025
Files
Collections
Artículos de revistas